FDA Lovenox Ruling Key To Competition Claims: Judge

Law360, New York (May 18, 2009, 12:00 AM EDT) -- A federal judge has dismissed Amphastar Pharmaceuticals Inc.'s fourth set of counterclaims against Aventis Pharmaceuticals Inc., ruling that federal regulators must take final action on the generics company's bid to produce its own version of anti-clotting drug Lovenox before the court can act on competition claims.

Judge Mariana R. Pfaelzer of the U.S. District Court for the Central District of California dropped the third amended counterclaims without prejudice on Friday but refused to grant Amphastar leave to amend its allegations until the U.S. Food and Drug...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.